WO2000029556A3 - Identification des glycosphingolipides qui favorisent la penetration du vih-1 dans les cellules - Google Patents

Identification des glycosphingolipides qui favorisent la penetration du vih-1 dans les cellules Download PDF

Info

Publication number
WO2000029556A3
WO2000029556A3 PCT/US1999/027341 US9927341W WO0029556A3 WO 2000029556 A3 WO2000029556 A3 WO 2000029556A3 US 9927341 W US9927341 W US 9927341W WO 0029556 A3 WO0029556 A3 WO 0029556A3
Authority
WO
WIPO (PCT)
Prior art keywords
glycosphingolipids
entry
cells
identification
hiv
Prior art date
Application number
PCT/US1999/027341
Other languages
English (en)
Other versions
WO2000029556A2 (fr
Inventor
Robert Blumenthal
Anu Puri
Peter Hug
Original Assignee
Us Health
Robert Blumenthal
Anu Puri
Peter Hug
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health, Robert Blumenthal, Anu Puri, Peter Hug filed Critical Us Health
Priority to AU17346/00A priority Critical patent/AU1734600A/en
Publication of WO2000029556A2 publication Critical patent/WO2000029556A2/fr
Publication of WO2000029556A3 publication Critical patent/WO2000029556A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01045—Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • AIDS & HIV (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)

Abstract

L'invention concerne la découverte de cofacteurs qui favorisent la fusion et la pénétration du VIH-1 dépendant de CD4. Elle se rapporte plus particulièrement à des instruments biotechnologiques, à des méthodes diagnostiques, prophylactiques et thérapeutiques et à des procédés d'utilisation de ces méthodes dans le traitement et la prévention de l'infection par le VIH-1 qui exploite les interactions entre gp120-gp41 et les glycosphingolipides.
PCT/US1999/027341 1998-11-17 1999-11-16 Identification des glycosphingolipides qui favorisent la penetration du vih-1 dans les cellules WO2000029556A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU17346/00A AU1734600A (en) 1998-11-17 1999-11-16 Identification of glycosphingolipids that promote hiv-1 entry into cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10890398P 1998-11-17 1998-11-17
US60/108,903 1998-11-17

Publications (2)

Publication Number Publication Date
WO2000029556A2 WO2000029556A2 (fr) 2000-05-25
WO2000029556A3 true WO2000029556A3 (fr) 2000-11-23

Family

ID=22324732

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/027341 WO2000029556A2 (fr) 1998-11-17 1999-11-16 Identification des glycosphingolipides qui favorisent la penetration du vih-1 dans les cellules

Country Status (2)

Country Link
AU (1) AU1734600A (fr)
WO (1) WO2000029556A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
JP4986335B2 (ja) * 2001-05-15 2012-07-25 生化学工業株式会社 Ｖｄａｃ機能阻害剤

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0298280A2 (fr) * 1987-06-30 1989-01-11 HAPGOOD, C.V., a Netherlands Antilles Limited Partnership Cellule d'origine animale dans laquelle on a introduit une protéine antigénique
WO1989002918A1 (fr) * 1987-09-22 1989-04-06 Arthur Allen Vandenbark Procede de modulation selective de l'expression et de la fonction d'un determinant de surface cellulaire, et production de nouvelles cellules humaines ainsi produites
EP0352766A2 (fr) * 1988-07-26 1990-01-31 FIDIA S.p.A. Synthèse de dérivés de glycosphingolipides pour utilisation dans la préparation d'adsorbants d'affinité et immunoadsorbants pour utilisation pour la purification d'anticorps, et de toxines et pour l'utilisation diagnostique
US5374548A (en) * 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
CA2163716A1 (fr) * 1995-11-24 1997-05-25 Clifford A. Lingwood Compositions pharmaceutiques a base de verotoxine et traitements medicaux qui l'utilisent
WO1997047318A1 (fr) * 1996-06-14 1997-12-18 Progenics Pharmaceuticals, Inc. Utilisations d'un recepteur de chemokines en vue de l'inhibition de l'infection a vih-1
WO1998026662A1 (fr) * 1996-12-19 1998-06-25 The Penn State Research Foundation Composes et methodes pour traiter et prevenir les maladies bacteriennes et virales
US5786368A (en) * 1993-05-13 1998-07-28 Monsanto Company Deoxygalactonojirimycin derivatives
US5795869A (en) * 1993-03-04 1998-08-18 Fidia S.P.A. Sulfated lyso-ganglioside derivatives
US5955293A (en) * 1989-10-17 1999-09-21 New England Medical Center Hospitals, Inc. Assays for shiga toxin and shiga-like toxins
US5962302A (en) * 1998-02-20 1999-10-05 Incyte Pharmaceuticals, Inc. Human N-acetylneuraminate lyase

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5374548A (en) * 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
EP0298280A2 (fr) * 1987-06-30 1989-01-11 HAPGOOD, C.V., a Netherlands Antilles Limited Partnership Cellule d'origine animale dans laquelle on a introduit une protéine antigénique
WO1989002918A1 (fr) * 1987-09-22 1989-04-06 Arthur Allen Vandenbark Procede de modulation selective de l'expression et de la fonction d'un determinant de surface cellulaire, et production de nouvelles cellules humaines ainsi produites
EP0352766A2 (fr) * 1988-07-26 1990-01-31 FIDIA S.p.A. Synthèse de dérivés de glycosphingolipides pour utilisation dans la préparation d'adsorbants d'affinité et immunoadsorbants pour utilisation pour la purification d'anticorps, et de toxines et pour l'utilisation diagnostique
US5955293A (en) * 1989-10-17 1999-09-21 New England Medical Center Hospitals, Inc. Assays for shiga toxin and shiga-like toxins
US5795869A (en) * 1993-03-04 1998-08-18 Fidia S.P.A. Sulfated lyso-ganglioside derivatives
US5786368A (en) * 1993-05-13 1998-07-28 Monsanto Company Deoxygalactonojirimycin derivatives
CA2163716A1 (fr) * 1995-11-24 1997-05-25 Clifford A. Lingwood Compositions pharmaceutiques a base de verotoxine et traitements medicaux qui l'utilisent
WO1997047318A1 (fr) * 1996-06-14 1997-12-18 Progenics Pharmaceuticals, Inc. Utilisations d'un recepteur de chemokines en vue de l'inhibition de l'infection a vih-1
WO1998026662A1 (fr) * 1996-12-19 1998-06-25 The Penn State Research Foundation Composes et methodes pour traiter et prevenir les maladies bacteriennes et virales
US5962302A (en) * 1998-02-20 1999-10-05 Incyte Pharmaceuticals, Inc. Human N-acetylneuraminate lyase

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
DELÉZAY O ET AL: "SPC3, a V3 Loop-derived synthetic peptide inhibitor of HIV-1 infection, binds to cell surface glycosphingolipids", BIOCHEMISTRY, vol. 35, 1996, pages 15663 - 15671, XP002141783 *
KARPAS A ET AL: "Aminosugar derivatives as potential anti-human immunodeficiency virus agents", PROC NATL ACAD SCI USA, vol. 85, December 1988 (1988-12-01), pages 9229 - 9233, XP002141782 *
MIZRACHI Y ET AL: "L-Cycloserine, an inhibitor of sphingolipid biosynthesis, inhibits HIV-1 cytopathic effects, replication, and infectivity", J ACQUI IMMUNE DEF SYNDR HUM RETROVIROL, vol. 11, no. 2, 1996, pages 137 - 141, XP000915063 *
PICARD LAURENT ET AL: "Possible role of nonprotein components of the plasma membrane in CD4-dependent membrane fusion and HIV entry.", PERSPECTIVES IN DRUG DISCOVERY AND DESIGN, vol. 5, 1996, pages 143 - 153, XP000923035, ISSN: 0928-2866 *
PURI A ET AL: "Human erythrocyte glycolipids promote HIV-1 envelope glycoprotein-mediated fusion of CD4+ cells", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATION, vol. 242, 6 January 1998 (1998-01-06), pages 219 - 225, XP002141781 *
PURI A ET AL: "The neutral glycosphingolipid globotriaosylceramide promotes fusion mediated by a CD4-dependent CXCR4-utilizing HIV type 1 envelope glycoprotein", PROC NATL ACAD SCI USA, vol. 95, 24 November 1998 (1998-11-24), pages 14435 - 14440, XP002141785 *
ROSENBERG, A.: "Purification of human.beta.- glucosyl ceramidase from cultured cells for potential enzyme replacement therapy in Gaucher's disease", PROC. FEBS MEET. (1980), 61(IND. CLIN. ENZYMOL.), 77-87, XP000915137 *
ZENG G ET AL: "Permanent alteration of endogenous gangliosides in neuroblastoma cells by stable transfection with antisense vector.", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, (1998 JUN 19) 845 431., XP000915132 *
ZENG GUICHAO ET AL: "Regulation of glycolipid synthesis in HL-60 cells by antisense oligodeoxynucleotides to glycosyltransferase sequences: Effect on cellular differentiation.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 92, no. 19, 1995, 1995, pages 8670 - 8674, XP002141784, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
WO2000029556A2 (fr) 2000-05-25
AU1734600A (en) 2000-06-05

Similar Documents

Publication Publication Date Title
WO2005065007A3 (fr) Procede et systeme d'authentification mettant en oeuvre des certificats exempts d'infrastructure
HK1036883A1 (en) Lithium-containing silicon/phosphates, method of preparation, and uses thereof.
AU5782900A (en) Secure, limited-access database system and method
WO1999051748A3 (fr) Proteines hybrides d'antigenes de mycobacterium tuberculosis et leurs utilisations
AU3912700A (en) Method and system for healthcare treatment, planning, and assessment
WO2001092994A3 (fr) Procede pour le cryptage biometrique de messages electroniques
MXPA02005782A (es) Sistema y metodo de doble red para autenticacion o autorizacion en linea.
AU2001261146A1 (en) Authentication and authorization epochs
AU6629400A (en) Authentication system and method
MXPA02005735A (es) Tratamieno de enzimas para infeccion.
WO2001022512A3 (fr) Dispositif a piles a combustibles et procede de fonctionnement correspondant
HK1045125A1 (en) Process for the decomposition of nitrous oxide.
ZA200107849B (en) Water treatment system and method using permeable embankments, weirs, walls, or the like.
WO2000020470A3 (fr) Dispersions aqueuses
WO2000039303A3 (fr) Polypeptides vih env modifies
WO2000052479A3 (fr) Procedes de diagnostic et de therapie des maladies des yeux associees aux drusen
AU2627800A (en) Treatment of lymphomas, leukemias, and leiomyomas
MXPA00007394A (es) Compuestos, composiciones y metodos para tratar o evitar infeccion de neumovirus y enfermedades asociadas.
WO2003003976A3 (fr) Compositions permettant d'enlever le cerumen humain
WO2000029556A3 (fr) Identification des glycosphingolipides qui favorisent la penetration du vih-1 dans les cellules
WO2001027247A3 (fr) Hydrolyse du lactose
AU2002365168A1 (en) Method and composition for treating and preventing hiv infection and aids
AU1820499A (en) Compounds and methods for the diagnosis and treatment of (b. microti) infection
EP0829539A3 (fr) Facteur ADN pour la sterilité male cytoplasmique et son utilisation
WO2000048584A3 (fr) Pyrroles d'aminoacyle d'aroyle destines au traitement des douleurs neuropathiques

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref country code: AU

Ref document number: 2000 17346

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ CZ DE DE DK DK DM EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ CZ DE DE DK DK DM EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase